The Clopidogrel and Aspirin After Surgery for Coronary Artery Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00776477 |
Recruitment Status : Unknown
Verified October 2008 by China National Center for Cardiovascular Diseases.
Recruitment status was: Recruiting
First Posted : October 21, 2008
Last Update Posted : October 21, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Atherosclerosis | Drug: clopidogrel and aspirin Drug: aspirin | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 300 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Study Start Date : | December 2007 |
Estimated Primary Completion Date : | December 2008 |

Arm | Intervention/treatment |
---|---|
Experimental: 1 |
Drug: clopidogrel and aspirin
clopidogrel 75mg daily and aspirin 100mg daily |
Active Comparator: 2 |
Drug: aspirin
aspirin 100mg daily |
- Vein graft patency examined by CT scan [ Time Frame: three months after surgery ]
- Incidence of major adverse coronary events Incidence of major bleeding events [ Time Frame: two years following surgery ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients undergoing primary multi-vessel CABG with at least two saphenous vein grafts, with or without the use of cardiopulmonary bypass.
Exclusion Criteria:
- Emergency surgery
- Valve surgery
- Redo CABG
- Left ventricle ejection fraction < 30%
- Preoperative use of clopidogrel (with the exception of the current admission)
- Preoperative use of warfarin
- Allergy to aspirin or clopidogrel
- History of cerebrovascular accident
- History of severe liver disease
- Morbid obesity
- Current malignancy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00776477
China, Beijing | |
Institute of cardiovascular diseases,Fuwai hospital | Recruiting |
Beijing, Beijing, China, 100037 | |
Contact: ge gao, MD 8601088398244 docgaoge@yahoo.com.cn | |
Principal Investigator: shengshou hu, MD |
Responsible Party: | shengshou hu,MD, Institute of cardiovascular diseases& Fuwai Hospital |
ClinicalTrials.gov Identifier: | NCT00776477 |
Other Study ID Numbers: |
NCCD20080101 |
First Posted: | October 21, 2008 Key Record Dates |
Last Update Posted: | October 21, 2008 |
Last Verified: | October 2008 |
Atherosclerosis Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Cardiovascular Diseases Aspirin Clopidogrel Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents |
Antirheumatic Agents Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Antipyretics Purinergic P2Y Receptor Antagonists Purinergic P2 Receptor Antagonists Purinergic Antagonists Purinergic Agents Neurotransmitter Agents |